anistreplase
Sign in to saveAlso known as BRL-26921, APSAC, t-plasminogen activator, Tissue-type plasminogen activator precursor, t- PA, tPA
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
Research
483 papers- Pharmacology of anistreplase.Clinical cardiology · 1990
- Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction.Clinical pharmacy · 1990
- Anistreplase: a novel thrombolytic agent for acute myocardial infarction.DICP : the annals of pharmacotherapy · 1990
- Alteplase and anistreplase in acute myocardial infarction.Drug and therapeutics bulletin · 1989
- An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.Journal of interventional cardiology · 1993
via PubMed
~1 min read
Encyclopedic overview
3 sectionsContents
- Uses
- History
- References
Anistreplase is a thrombolytic drug. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC). As a thrombolytic drug, it is used to treat blood clots in emergency situations.
== Uses == Anistreplase is used to treat blood clots in emergency situations such as myocardial infarction. Early treatment gives better outcomes.
Excerpted from Wikipedia’s “anistreplase” article, available under the CC BY-SA 4.0 licence.
Available in 8 languages
via Wikidata sitelinks · CC0